PRPO

$29.35

Post-MarketAs of Mar 17, 8:00 PM UTC

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$29.35
Potential Upside
5%
Whystock Fair Value$30.82
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media t...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$51.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-9.76%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.96

Recent News

Zacks
Dec 24, 2025

Top Stock Reports for AbbVie, Coca-Cola & Chevron

ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 19, 2025

Precipio Stock Up Following Solid Q3 Earnings and Improved Cash Flow

PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Nov 18, 2025

Precipio Inc (PRPO) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Precipio Inc (PRPO) achieves positive adjusted EBITDA for the first time, marking a significant financial milestone amidst strategic investments and operational challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Sep 23, 2025

The Zacks Analyst Blog Highlights HSBC, American Express, TotalEnergies, Armanino Foods of Distinction and Precipio

HSBC, American Express, TotalEnergies, Armanino Foods, and Precipio stand out in Zacks' latest research highlights.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Aug 15, 2025

Precipio Second Quarter 2025 Earnings: EPS: US$0.049 (vs US$0.83 loss in 2Q 2024)

NasdaqCM:PRPO 1 Year Share Price vs Fair Value Explore Precipio's Fair Values from the Community and select yours...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.